Sildenafil improves diabetic vascular activity through suppressing endothelin receptor A, iNOS and NADPH oxidase which is comparable with the endothelin receptor antagonist CPU0213 in STZ-injected rats

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 7, 2011, Pages 943-951

  Luo, Lu ^a   Dai, De Zai ^a   Cheng, Yu Si ^a   Zhang, Qi ^b   Yuan, Wen Jun ^c,d   Dai, Yin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING TECH UNIVERSITY   (China)

^c NINGXIA MEDICAL UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

diabetes; endothelin receptor antagonists; inflammatory cytokines; sildenafil; vascular relaxation

Indexed keywords

ACETYLCHOLINE; BIOLOGICAL MARKER; CHOLESTEROL; CPU 0213; ENDOTHELIN A RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; GELATINASE B; GLUTATHIONE PEROXIDASE; INDUCIBLE NITRIC OXIDE SYNTHASE; MALONALDEHYDE; PHENYLEPHRINE; PROTEIN P67; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SILDENAFIL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOAVAILABILITY; BLOOD VESSEL FUNCTION; BLOOD VESSEL TONE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; DRUG STRUCTURE; ENZYME BLOOD LEVEL; ENZYME REPRESSION; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; RAT; THORACIC AORTA; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; VASCULAR DISEASE; VASODILATATION;

ANIMALS; AORTA, THORACIC; BIOLOGICAL MARKERS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; GENE EXPRESSION REGULATION; MALE; MATRIX METALLOPROTEINASE 9; MUSCLE, SMOOTH, VASCULAR; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; PYRAZOLES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; RNA, MESSENGER; SULFONES;

EID: 79958053356     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01268.x     Document Type: Article

References (38)

1. Versari D, et al,. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009; 32 (Suppl 2): S314-S321.
2. Kirsch M, et al,. Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-cGMP signaling. FASEB J 2008; 22: 30-40.
3. Mather KJ, et al,. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes 2004; 53: 2060-2066. (Pubitemid 38970755)
4. Su W, et al,. Upregulated endothelin system in diabetic vascular dysfunction and early retinopathy is reversed by CPU0213 and total triterpene acids from Fructus Corni. Clin Exp Pharmacol Physiol 2007; 34: 1228-1233. (Pubitemid 350013233)
5. Type 2 diabetes: target HbA1c of about 7%. Prescrire Int 2009; 18: 177.
6. Gore MO, McGuire DK,. Cardiovascular disease and type 2 diabetes mellitus: regulating glucose and regulating drugs. Curr Cardiol Rep 2009; 11: 258-263.
7. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
8. Vladimirova-Kitova LG, et al,. Evaluation of the relationship between flow-mediated vasodilation and some atherogenic risk markers in severe hypercholesterolemia. Folia Med (Plovdiv) 2008; 50: 22-28.
9. Luo L, et al,. Hypercholesterolaemia induces early renal lesions characterized by upregulation of MMP-9 and iNOS and ET(A)R: alleviated by a dual endothelin receptor antagonist CPU0213 and simvastatin. J Pharm Pharmacol 2009; 61: 775-780.
10. Brownlee M,. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820. (Pubitemid 34000785)
11. Xu M, et al,. Normalizing NADPH oxidase contributes to attenuating diabetic nephropathy by the dual endothelin receptor antagonist CPU0213 in rats. Am J Nephrol 2009; 29: 252-256.
12. Xu J, et al,. The endothelin receptor antagonist CPU0213 is more effective than aminoguanidine to attenuate isoproterenol-induced vascular abnormality by suppressing overexpression of NADPH oxidase ETA, ETB, and MMP9 in the vasculature. J Cardiovasc Pharmacol 2008; 52: 42-48.
13. Peng HJ, et al,. The separate roles of endothelin receptors participate in remodeling of matrix metalloproteinase and connexin 43 of cardiac fibroblasts in maladaptive response to isoproterenol. Eur J Pharmacol 2010; 634: 101-106.
14. Ceriello A, Motz E,. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004; 24: 816-823. (Pubitemid 38620857)
15. Schulz R, et al,. Recent advances in the understanding of the role of nitric oxide in cardiovascular homeostasis. Pharmacol Ther 2005; 108: 225-256. (Pubitemid 41691866)
16. Cui B, et al,. CPU0213, a non-selective ETA/ETB receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats. Clin Exp Pharmacol Physiol 2009; 36: 169-175.
17. Kalani M,. The importance of endothelin-1 for microvascular dysfunction in diabetes. Vasc Health Risk Manag 2008; 4: 1061-1068.
18. Schäfer A, et al,. Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus. Br J Pharmacol 2008; 153: 886-893. (Pubitemid 351328925)
19. El-Sakka AI,. Efficacy of sildenafil citrate in treatment of erectile dysfunction: effect of type 2 diabetes. Eur Urol 2004; 46: 503-509. (Pubitemid 39200861)
20. Zhang XH, et al,. Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes. J Sex Med 2006; 3: 253-264.
21. Xu M, et al,. Upregulated NADPH oxidase contributes to diabetic testicular complication and is relieved by strontium fructose 1,6-diphosphate. Exp Clin Endoc Diab 2010; 118: 459-465.
22. Pennathur S, Heinecke JW,. Mechanisms for oxidative stress in diabetic cardiovascular disease. Antioxid Redox Signal 2007; 9: 955-969. (Pubitemid 46919596)
23. Schulz R, et al,. Recent advances in the understanding of the role of nitric oxide in cardiovascular homeostasis. Pharmacol Ther 2005; 108: 225-256. (Pubitemid 41691866)
24. Cheng YS, et al,. Isoproterenol disperses distribution of NADPH oxidase, MMP-9, and pPKCepsilon in the heart, which are mitigated by endothelin receptor antagonist CPU0213. Acta Pharmacol Sin 2009; 30: 1099-1106.
25. Mayhan WG, et al,. Age-related alterations in reactivity of cerebral arterioles: role of oxidative stress. Microcirculation 2008; 15: 225-236.
26. Calderone V, et al,. Anti-ischaemic activity of an antioxidant aldose reductase inhibitor on diabetic and non-diabetic rat hearts. J Pharm Pharmacol 2010; 62: 107-113.
27. Stintzing S, et al,. Overexpression of MMP9 and tissue factor in unstable carotid plaques associated with Chlamydia pneumoniae, inflammation, and apoptosis. Ann Vasc Surg 2005; 19: 310-319. (Pubitemid 40884083)
28. Brink PR, et al,. Experimental diabetes alters connexin43 derived gap junction permeability in short-term cultures of rat corporeal vascular smooth muscle cells. J Urol 2006; 175: 381-386. (Pubitemid 41797206)
29. Zheng YF, et al,. NaHS ameliorates diabetic vascular injury by correcting depressed connexin 43 and 40 in the vasculature in streptozotocin-injected rats. J Pharm Pharmacol 2010; 62: 615-621.
30. Chang SH, et al,. Anti-inflammatory effects of Artemisia princeps in antigen-stimulated T cells and regulatory T cells. J Pharm Pharmacol 2009; 61: 1043-1050.
31. Sharma SB, et al,. Antidiabetogenic action of Morus rubra L. leaf extract in streptozotocin-induced diabetic rats. J Pharm Pharmacol 2010; 62: 247-255.
32. Ebrahimi F, et al,. Sildenafil decreased cardiac cell apoptosis in diabetic mice: reduction of oxidative stress as a possible mechanism. Can J Physiol Pharmacol 2009; 87: 556-564.
33. Blonde L,. Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials. Curr Med Res Opin 2006; 22: 2111-2120. (Pubitemid 44789975)
34. Vardi M, Nini A,. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database Syst Rev 2007; (1): CD002187.
35. Hatzimouratidis K, Hatzichristou DG,. Phosphodiesterase type 5 inhibitors: unmet needs. Curr Pharm Des 2009; 15: 3476-3485.
36. Aversa A, et al,. Chronic administration of sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabet Me 2008; 25: 37-44.
37. Morano S, et al,. Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. Eur Urol 2007; 52: 1768-1774.
38. Mouchaers KT, et al,. Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 2009; 297: H200-H207.